ScreenerHero

EPRX Eupraxia Pharmaceuticals Inc.

TSX · CA · Healthcare · Biotechnology · eupraxiapharma.com
10.69CAD+3.59%Mkt Cap: 496.58M $P/E: —

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug de…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
ARGENX SE
$55.45BUSDP/E 35.2
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$42.34BUSDP/E 18.1
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
GMAB
Genmab A/S
$20.52BUSDP/E 27.1
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD
HeadlineSourceTime
Older
Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice

On August 13, Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) released new data from its Phase 1b/2a RESOLVE trial showing that odynophagia, the medical term for painful swallowing, faded dramatically in patients treated with its lead drug candidate EP-104GI. In the highest-dose cohorts, moderate to severe odynophagia fell from 62% of patients at baseline to just 25% by […]

Insider Monkey
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?

The consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks